Mott: UK pharmas may double your money in five years

PSigma's Bill Mott has tipped UK pharmaceutical giants AstraZeneca and GlaxoSmithKline to double investors' cash over the next three to five years.

Mott, running the group’s £430m Income fund, said the combination of high dividends and share price growth should deliver a total return of 100% to investors within the next five years. “Pharmaceuticals are yielding better than cash and 10-year gilts, at 4%-6%, and I could easily see the likes of GlaxoSmithKline and Astra delivering a total return approaching 100% over the next three to five years,” he said. Glaxo is Mott’s largest holding at 6.2%, with Astra accounting for 4.1% of the fund. Elsewhere, Mott continues to shun UK domestic facing stocks, clashing with peers who are st...